ES2601127T3 - Derivado de pirazol y su uso con fines médicos - Google Patents

Derivado de pirazol y su uso con fines médicos Download PDF

Info

Publication number
ES2601127T3
ES2601127T3 ES13787714.8T ES13787714T ES2601127T3 ES 2601127 T3 ES2601127 T3 ES 2601127T3 ES 13787714 T ES13787714 T ES 13787714T ES 2601127 T3 ES2601127 T3 ES 2601127T3
Authority
ES
Spain
Prior art keywords
medical purposes
pyrazole derivative
glucopyranosyloxy
dimethylpropionamide
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13787714.8T
Other languages
English (en)
Spanish (es)
Inventor
Masayuki Isaji
Masaaki TAKEMURA
Hidetoshi Isawa
Yukihiko Hotei
Itaru MIYASHITA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2601127T3 publication Critical patent/ES2601127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13787714.8T 2012-05-07 2013-05-02 Derivado de pirazol y su uso con fines médicos Active ES2601127T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012105847 2012-05-07
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (1)

Publication Number Publication Date
ES2601127T3 true ES2601127T3 (es) 2017-02-14

Family

ID=49550709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13787714.8T Active ES2601127T3 (es) 2012-05-07 2013-05-02 Derivado de pirazol y su uso con fines médicos

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
JP5663699B2 (ja) * 2012-05-07 2015-02-04 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途
MY176162A (en) 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
CA2952405A1 (en) * 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for stabilizing the same
WO2019191352A1 (en) 2018-03-28 2019-10-03 Avolynt Method for treating post-prandial hypoglycemia
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069247B1 (en) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
AU2008344436B2 (en) * 2007-12-27 2013-08-29 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
WO2009128421A1 (ja) 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩
WO2011002001A1 (ja) * 2009-07-01 2011-01-06 キッセイ薬品工業株式会社 ピラゾール誘導体とビグアナイド薬との組み合わせ医薬
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP5663699B2 (ja) * 2012-05-07 2015-02-04 キッセイ薬品工業株式会社 ピラゾール誘導体及びその医薬用途

Also Published As

Publication number Publication date
PL2848254T3 (pl) 2017-03-31
JP5663699B2 (ja) 2015-02-04
JP6105546B2 (ja) 2017-03-29
AU2013258566B2 (en) 2017-03-16
CN104284665A (zh) 2015-01-14
PT2848254T (pt) 2016-10-05
CA2872002C (en) 2019-01-15
DK2848254T3 (en) 2016-10-31
CN104284665B (zh) 2016-11-16
HK1204773A1 (en) 2015-12-04
EP2848254A1 (en) 2015-03-18
EP2848254A4 (en) 2015-07-15
RU2602739C2 (ru) 2016-11-20
RU2014149181A (ru) 2016-06-27
BR112014027841B1 (pt) 2022-08-09
EP2848254B1 (en) 2016-08-03
MX2014013696A (es) 2015-02-05
CA2872002A1 (en) 2013-11-14
AU2013258566A1 (en) 2014-11-27
MX359988B (es) 2018-10-18
KR20150013671A (ko) 2015-02-05
BR112014027841A2 (pt) 2017-06-27
US20150141631A1 (en) 2015-05-21
US20160129031A1 (en) 2016-05-12
JP2015083580A (ja) 2015-04-30
BR112014027841A8 (pt) 2021-09-28
JPWO2013168671A1 (ja) 2016-01-07
KR101868991B1 (ko) 2018-06-19
US9694027B2 (en) 2017-07-04
WO2013168671A1 (ja) 2013-11-14
US9273085B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
JP2015083580A5 (enExample)
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
ES2555778T3 (es) Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
AR073265A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
ES2660019T3 (es) Parche que contiene diclofenaco y tiocolchicósido
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
JP2016538288A5 (enExample)
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
ES2507517T3 (es) Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad